The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | Updates from the Phase II AERN trial: nivolumab and radiotherapy for the treatment of R/R HL
Paul Jan Bröckelmann, MD, University Hospital of Cologne, Cologne, Germany, shares some updates from the Phase II AERN trial (NCT03480334) evaluating the use of nivolumab and radiotherapy for the treatment of patients with relapsed/refractory (R/R) Hodgkin lymphoma (HL) who have failed prior anti-PD1 treatment. Dr Bröckelmann highlights some results from this trial, drawing focus on the abscopal effect of this treatment approach. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
